Skip to main content
Clinical Trials/NCT02897544
NCT02897544
Completed
N/A

Developing a Health Education Intervention for Breast Cancer Survivorship

University of California, San Francisco1 site in 1 country20 target enrollmentSeptember 2016
ConditionsBreast Cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
University of California, San Francisco
Enrollment
20
Locations
1
Primary Endpoint
Change in quality of life over 6 months
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to develop and test a 6 month manualized Health Education intervention in recent breast cancer survivors.

Detailed Description

Post-treatment cancer survivorship is often associated with a void in care given the drop-off in support provided to survivors from the medical team as well as family and friends. The investigators aim to develop and test a Health Education intervention in breast cancer survivors. Specifically, the investigators aim to develop the manualized Health Education intervention; to assess feasibility; and to provide preliminary data on the effects of the intervention. The data from this pilot study will be used to inform future study.

Registry
clinicaltrials.gov
Start Date
September 2016
End Date
June 4, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Female breast cancer survivor who is over 1 month and less than 24 months beyond the completion of primary therapy (surgery, radiation, and chemotherapy)
  • Having received chemotherapy as part of their primary therapy for breast cancer
  • Be in complete remission
  • Aged 18 years or older
  • Able to read, write, and understand English
  • Karnofsky Performance Status (KPS) greater than or equal to 60
  • Have impaired quality of life
  • Ability to give informed consent

Exclusion Criteria

  • Receiving chemotherapy or radiotherapy at the time of study enrollment. Anti-her2 directed therapy is not exclusionary.
  • Being within 1 month (before or after) of surgery for breast cancer (including breast reconstructive surgery). Smaller surgical procedures such as implant exchange are not exclusionary.
  • Patients on adjuvant hormone therapy for less than 2 months
  • Have surgery for breast cancer or breast reconstructive surgery planned during the initial 6 month study period. Smaller surgical procedures such as implant exchange are not exclusionary.

Outcomes

Primary Outcomes

Change in quality of life over 6 months

Time Frame: Baseline, 3 months, 6 months

The investigators will use the EORTC QLQ C30 in conjunction with a breast cancer-specific subscale, BR23, to collect data on quality of life and cancer-related symptoms.

Secondary Outcomes

  • Change in diet over 6 months(Baseline, 3 months, 6 months)
  • Change in pain over 6 months(Baseline, 3 months, 6 months)
  • Change in fatigue over 6 months(Baseline, 3 months, 6 months)
  • Change in sleep quality over 6 months(Baseline, 3 months, 6 months)
  • Change in anxiety over 6 months(Baseline, 3 months, 6 months)
  • Change in depressive symptoms over 6 months(Baseline, 3 months, 6 months)

Study Sites (1)

Loading locations...

Similar Trials